Integra LifeSciences Holdings Corporation (NASDAQ: IART) and ICU Medical (NASDAQ:ICUI) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Valuation and Earnings

This table compares Integra LifeSciences Holdings Corporation and ICU Medical’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Integra LifeSciences Holdings Corporation $1.05 billion 3.73 $240.98 million $0.82 61.24
ICU Medical $772.05 million 4.38 $92.48 million $2.62 64.62

Integra LifeSciences Holdings Corporation has higher revenue and earnings than ICU Medical. Integra LifeSciences Holdings Corporation is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.7% of Integra LifeSciences Holdings Corporation shares are owned by institutional investors. Comparatively, 77.1% of ICU Medical shares are owned by institutional investors. 21.5% of Integra LifeSciences Holdings Corporation shares are owned by company insiders. Comparatively, 15.9% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Integra LifeSciences Holdings Corporation and ICU Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra LifeSciences Holdings Corporation 0 2 8 0 2.80
ICU Medical 0 2 1 0 2.33

Integra LifeSciences Holdings Corporation currently has a consensus target price of $52.35, suggesting a potential upside of 4.24%. Given Integra LifeSciences Holdings Corporation’s stronger consensus rating and higher probable upside, research analysts clearly believe Integra LifeSciences Holdings Corporation is more favorable than ICU Medical.

Volatility and Risk

Integra LifeSciences Holdings Corporation has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Profitability

This table compares Integra LifeSciences Holdings Corporation and ICU Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Integra LifeSciences Holdings Corporation 6.27% 16.79% 7.35%
ICU Medical 6.10% 7.56% 6.20%

Summary

Integra LifeSciences Holdings Corporation beats ICU Medical on 11 of the 14 factors compared between the two stocks.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

ICU Medical Company Profile

ICU Medical, Inc. is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The primary critical care products it manufactures are Hemodynamic Monitoring Systems, SafeSet Closed Blood Sampling and Conservation System, Transpac Consumable Blood Pressure Transducers and Other Critical Care Products. The primary oncology products it manufactures are ChemoLock Needlefree CSTD, ChemoClave Needlefree CSTD and Diana Hazardous Drug Compounding System. As of December 31, 2016, its products were used in acute care hospitals and ambulatory clinics in more than 65 countries throughout the world.

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.